GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (OTCPK:CLVSF) » Definitions » Net-Net Working Capital

CLVSF (CellaVision AB) Net-Net Working Capital : $0.51 (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is CellaVision AB Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

CellaVision AB's Net-Net Working Capital for the quarter that ended in Mar. 2025 was $0.51.

The industry rank for CellaVision AB's Net-Net Working Capital or its related term are showing as below:

CLVSF's Price-to-Net-Net-Working-Capital is ranked worse than
87.39% of 436 companies
in the Medical Devices & Instruments industry
Industry Median: 6.83 vs CLVSF: 36.96

CellaVision AB Net-Net Working Capital Historical Data

The historical data trend for CellaVision AB's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Net-Net Working Capital Chart

CellaVision AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.12 0.01 0.19 0.35

CellaVision AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.17 0.27 0.35 0.51

Competitive Comparison of CellaVision AB's Net-Net Working Capital

For the Medical Devices subindustry, CellaVision AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Price-to-Net-Net-Working-Capital falls into.


;
;

CellaVision AB Net-Net Working Capital Calculation

CellaVision AB's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(13.603+0.75 * 9.36+0.5 * 11.363-17.963
-0-0)/23.852
=0.35

CellaVision AB's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2025 is calculated as

Net-Net Working Capital(Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(17.993+0.75 * 11.461+0.5 * 11.78-20.264
-0-0)/23.852
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


CellaVision AB  (OTCPK:CLVSF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


CellaVision AB Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.

CellaVision AB Headlines

From GuruFocus

Q4 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2024 CellaVision AB Earnings Call Transcript

By GuruFocus News 10-25-2024

3 Scandinavian Companies With Strong Margin Growth

By James Li James Li 12-01-2020

Q1 2022 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q2 2024 CellaVision AB Earnings Call Transcript

By GuruFocus Research 07-21-2024

Q2 2023 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q1 2021 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q1 2020 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2019 CellaVision AB Earnings Call Transcript

By GuruFocus Research 03-03-2024